You are here

FDA Denies Approval for Expanded Use of Xarelto (Rivaroxaban) in ACS

Second rejection for blood thinner (Mar. 4)

For the second time, the FDA has refused to approve the expanded use of the blood thinner Xarelto (rivaroxaban) to reduce the risk of heart attacks and stroke in patients with acute coronary syndrome (ACS), according to a Reuters report.

The drug was turned down in June for the same indication when the agency expressed concerns regarding missing trial data and the risk of bleeding.

In response, the drug’s developer, Johnson & Johnson, submitted data related to patients who had withdrawn from a pivotal clinical trial of Xarelto. The new information was also considered insufficient.

J&J said it is reviewing the new rejection letter.

Xarelto is approved for six other indications, including reducing the risk of blood clots in the legs and lungs of patients who have had hip- or knee-replacement surgery, and preventing strokes in patients with atrial fibrillation.

Source: Reuters; March 4, 2013.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens